Advances in antibody-based therapy in oncology

被引：65

作者：

Zinn, Sacha ^{[1
,2
]}

Vazquez-Lombardi, Rodrigo ^{[1
,2
,7
]}

Zimmermann, Carsten ^{[3
,4
]}

Sapra, Puja ^{[5
]}

Jermutus, Lutz ^{[6
]}

Christ, Daniel ^{[1
,2
]}

机构：

[1] Garvan Inst Med Res, Sydney, NSW, Australia

[2] Univ New South Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia

[3] Univ San Diego, Knauss Sch Business, San Diego, CA USA

[4] Univ Calif San Diego, La Jolla, CA USA

[5] AstraZeneca, Oncol R&D, Biol Engn & Targeted Delivery, Gaithersburg, MD USA

[6] Res & Early Dev, AstraZeneca, BioPharmaceut R&D, Cambridge, England

[7] Engimmune Therapeut, Allschwil, Switzerland

来源：

NATURE CANCER | 2023年 / 4卷 / 02期

基金：

英国医学研究理事会;

关键词：

C-RECEPTOR POLYMORPHISMS; I-RELATED RECEPTOR; T-CELL EXHAUSTION; SERUM HALF-LIFE; FC-GAMMA-RIIB; MONOCLONAL-ANTIBODY; DEPENDENT MECHANISMS; ANTITUMOR IMMUNITY; AGONISTIC ANTIBODY; EFFECTOR FUNCTIONS;

D O I：

10.1038/s43018-023-00516-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this review article, Christ and colleagues discuss the recent developments in antibody-based cancer therapies. Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discuss molecular structure and mechanisms of action and provide updates on clinical development and practice.

引用

页码：165 / 180

页数：16

共 50 条

[1] Advances in antibody-based therapy in oncology
Sacha Zinn
Rodrigo Vazquez-Lombardi
Carsten Zimmermann
Puja Sapra
Lutz Jermutus
Daniel Christ
[J]. Nature Cancer, 2023, 4 : 165 - 180
[2] Advances in Antibody-based Proteomic Analysis
Stokes, Matthew P.
Gu, Hongbo
Farnsworth, Charles L.
Ren, Jian Min
Lee, Kimberly A.
Silva, Jeffrey C.
[J]. MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (08) : S22 - S22
[3] Antibody-based cancer therapy
Goydel, Rebecca S.
Rader, Christoph
[J]. ONCOGENE, 2021, 40 (21) : 3655 - 3664
[4] Antibody-based cancer therapy
Rebecca S. Goydel
Christoph Rader
[J]. Oncogene, 2021, 40 : 3655 - 3664
[5] Monoclonal antibody-based therapy
Tecucianu, S
[J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S39 - S39
[6] Antibody-based cancer therapy
Baxevanis, Constantin N.
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (04) : 441 - 452
[7] Antibody-based therapy of leukaemia
Morris, John C.
Waldmann, Thomas A.
[J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2009, 11
[8] ANTIBODY-BASED THERAPY OF MDS
Brunner, A.
[J]. LEUKEMIA RESEARCH, 2023, 128
[9] Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Davda, Jasmine
Declerck, Paul
Hu-Lieskovan, Siwen
Hickling, Timothy P.
Jacobs, Ira A.
Chou, Jeffrey
Salek-Ardakani, Shahram
Kraynov, Eugenia
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10] Development of antibody-based therapeutics for oncology indications
Yan, Li
Zhu, Zhenping
[J]. DRUG DEVELOPMENT RESEARCH, 2006, 67 (09) : 699 - 728

← 1 2 3 4 5 →